



July 30, 2010

## Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2011 <under Japanese GAAP>

Listed company name: **DAIICHI SANKYO COMPANY, LIMITED**

Listed exchanges: First Section of the Tokyo, Osaka, and Nagoya stock exchanges

Stock code number: 4568

URL: <http://www.daiichisankyo.com>

Representative: Mr. Joji Nakayama, Representative Director and President & CEO

Contact: Mr. Toshiaki Sai, Corporate Officer, General Manager of Corporate Communications

Telephone: +81-3-6225-1125 (Investor Relations); +81-3-6225-1126 (Public Relations)

Scheduled date of Quarterly Report filing: August 11, 2010

Scheduled date of dividend payments: –

Preparing supplementary material (Reference Data) on quarterly financial results: Yes

Holding quarterly information meeting: Yes (for institutional investors, analysts and the press)

(All amounts have been rounded down to the nearest million yen.)

### 1. Consolidated Financial Results for the First Quarter of Fiscal 2010

(from April 1, 2010 to June 30, 2010)

#### (1) Consolidated Financial Results (cumulative)

(Percentages indicate changes over the same period in the previous fiscal year.)

	Net sales		Operating income		Ordinary income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
First three months of fiscal 2010	256,427	12.9	61,061	128.1	70,093	877.7
First three months of fiscal 2009	227,123	11.5	26,766	(33.1)	7,168	(82.5)

	Net income		Basic net income per share	Diluted net income per share
	Millions of yen	%	Yen	Yen
First three months of fiscal 2010	33,073	–	46.98	46.95
First three months of fiscal 2009	(6,439)	–	(9.15)	–

#### (2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of June 30, 2010	1,468,277	890,295	57.8	1,205.15
As of March 31, 2010	1,489,510	889,508	57.4	1,215.62

Reference: Equity As of June 30, 2010: 848,337 million yen As of March 31, 2010: 855,706 million yen

## 2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal 2009	–	30.00	–	30.00	60.00
Fiscal 2010	–	–	–	–	–
Fiscal 2010 (Forecast)	–	30.00	–	30.00	60.00

Note: Revision of the forecast in the first quarter of fiscal 2010: No

## 3. Forecasts of Consolidated Results for Fiscal 2010

(from April 1, 2010 to March 31, 2011)

(Percent changes indicate changes from in the prior fiscal year.)

	Net sales		Operating income		Ordinary income		Net income		Basic net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First six months	490,000	4.1	50,000	(1.7)	48,000	(8.2)	25,000	33.7	35.52
Full year	980,000	2.9	90,000	(5.8)	85,000	(17.6)	45,000	7.5	63.93

Note: Revision of the forecasts in the first quarter of fiscal 2010: No

## 4. Others (For details, please refer to “2. Other Information” on page 3 of the Attached Material)

### (1) Changes in subsidiaries during the quarter: Yes

Newly included: None Excluded: One (Asubio Pharma Co., Ltd.)

Note: Changes in specified subsidiaries resulting in a change in scope of consolidation in the current quarter

### (2) Application of simplified accounting methods as well as specific accounting methods: Yes

Note: Application of simplified accounting methods as well as specific accounting methods for preparing quarterly consolidated financial statements

### (3) Changes in accounting principles and procedures, and methods of presentation

#### 1) Changes due to revisions to accounting standards: Yes

#### 2) Changes due to other reasons: No

Note: Changes in accounting principles, procedures, and methods of presentation related to the preparation of the quarterly consolidated financial statements to be stated in the section of “Summary of Changes in Accounting Policies and Procedures, and Methods of Presentation”

### (4) Number of common shares issued

#### 1) Total number of shares issued at the end of the period (including treasury stock)

As of June 30, 2010	709,011,343 shares
As of March 31, 2010	709,011,343 shares

#### 2) Number of shares in treasury at the end of the period

As of June 30, 2010	5,084,108 shares
As of March 31, 2010	5,084,489 shares

#### 3) Average number of shares during the period (cumulative from the beginning of the fiscal year)

First three months ended June 30, 2010	703,926,178 shares
First three months ended June 30, 2009	703,935,201 shares

\* Indication regarding execution of quarterly procedures

This quarterly financial results report is not subject to the quarterly review procedures in accordance with the Financial Instruments and Exchange Act. At the time of disclosure of this quarterly financial results report, the quarterly review procedures in accordance with the Financial Instruments and Exchange Act are incomplete.

\* Disclaimer regarding forward-looking information including appropriate use of forecasted financial results

The forecasted statement shown in these materials are based on information currently available and certain assumptions that the Company regards as reasonable. Actual performance and other results may differ from these forecasted figures due to various factors.

Please see (3) *Qualitative Information about Forecasts of Consolidated Results for Fiscal 2010 of 1. Qualitative Information about Consolidated Results for the First Three Months* on page 3 for assumption that the above forecasts were based on and related matters.

**Attached Material**

**Index**

- 1. Qualitative Information about Consolidated Results for the First Three Months..... 2
  - (1) Qualitative Information about Consolidated Operating Results ..... 2
  - (2) Qualitative Information about Consolidated Financial Position ..... 3
  - (3) Qualitative Information about Forecasts of Consolidated Results for Fiscal 2010..... 3
- 2. Other Information ..... 3
  - (1) Summary of Changes in Significant Subsidiaries ..... 3
  - (2) Summary of Simplified Accounting Methods as well as Specific Accounting Methods..... 3
  - (3) Summary of Changes in Accounting Policies, Procedures, and Methods of Presentation ..... 4
  - (4) Summary of Material Events related to Assumption of Going-Concern ..... 4
- 3. Quarterly Consolidated Financial Statements..... 5
  - (1) Consolidated Balance Sheets ..... 5
  - (2) Consolidated Statements of Income..... 7
  - (3) Consolidated Statements of Cash Flows ..... 9
  - (4) Note related to Assumption of Going-Concern.....11
  - (5) Segment Information .....11
  - (6) Notes on Substantial Changes in the Amount of Shareholders' Equity ..... 12

## 1. Qualitative Information about Consolidated Results for the First Three Months

### (1) Qualitative Information about Consolidated Operating Results

Consolidated Financial Results

(Millions of yen; rounded down to the nearest million yen)

	First three months of fiscal 2009	First three months of fiscal 2010	Difference from the same period in the previous year (%)
Net sales	227,123	256,427	29,303 (12.9%)
Operating income	26,766	61,061	34,295 (128.1%)
Ordinary income	7,168	70,093	62,924 (877.7%)
Net income	(6,439)	33,073	39,513 (-)

Exchange rates in the first three months of fiscal 2010: ¥92.0/USD, ¥117.0/EUR, ¥1.98/INR

Exchange rates in the first three months of fiscal 2009: ¥97.3/USD, ¥132.6/EUR, ¥1.89/INR

In the three months from April 1 to June 30, 2010, Daiichi Sankyo and its consolidated subsidiaries (“the Group”) posted net sales of ¥256.4 billion, a year-on-year gain of 12.9%. Despite a stronger yen compared with the same period of the previous year, this gain in net sales was mainly due to sales growth of the antihypertensive agent olmesartan and the sales contribution of ¥54.8 billion by Ranbaxy Laboratories Limited (“Ranbaxy”). Operating income increased 128.1% to ¥61.1 billion thanks to the contribution of Ranbaxy and cost containment measures, and ordinary income jumped 877.7% to ¥70.1 billion mainly on the back of a decrease in foreign exchange losses and the occurrence at Ranbaxy of gains on valuation of derivatives. Note that income taxes in FY2009 were at a high level due to prior-year tax adjustments. In the period under review, however, there were no such special factors and the Group posted a net income of ¥33.1 billion compared with a net loss of ¥6.4 billion in the same period of the previous year.

#### [Reportable Segments]

##### i. Daiichi Sankyo Group

The Daiichi Sankyo Group posted net sales of ¥201.6 billion, a year-on-year gain of 2.1%.

##### a. Japan

Net sales in Japan increased 3.1% year on year to ¥132.5 billion.

Sales of prescription drugs rose 5.3% to ¥112.2 billion, boosted by sales growth of antihypertensive agent *Olmetec*®, the anti-inflammatory analgesic *Loxonin*® and other brands.

Also contributing to sales was the antihypertensive agent *Rezaltas*® (a combination agent containing the angiotensin II receptor blocker olmesartan medoxomil and the calcium channel blocker azelnidipine), which was launched in April.

Sales from royalty income and exports to overseas licenses fell 9.9% year on year to ¥10.2 billion due to the effect of the stronger yen and the decline in sales of levofloxacin, a synthetic antibacterial agent.

Net sales of Healthcare (the OTC business) totaled ¥9.3 billion, falling 2.7% year on year. This was due to lower sales of *Patecs*® and others.

## **b. North America**

In North America, although the shift toward a stronger yen affected sales due to translation effects, sales continued to grow in local currency terms, and net sales increased 4.2% year on year to ¥48.3 billion. Major contributors to growth included the antihypertensive agents *Benicar*® and *AZOR*®, the antihyperlipidemic agent and treatment for type 2 diabetes *Welchol*®, and the anemia treatment *Venofer*®.

## **c. Europe**

In Europe, although there was growth in sales of the antihypertensive agents *Olmotec*® and *Sevikar*®, net sales decreased 14.4% year on year to ¥14.8 billion mainly reflecting the effect of foreign exchange due to the stronger yen.

## **d. Other regions**

In other regions, net sales rose 12.7% year on year to ¥5.9 billion, thanks mainly to sales increases in China, South Korea and Brazil.

## **ii. Ranbaxy Group**

Net sales of the Ranbaxy Group rose 84.7% year on year to ¥54.8 billion. Contributing to sales in the U.S. was the antiviral drug valacyclovir.

## **(2) Qualitative Information about Consolidated Financial Position**

As of June 30, 2010, net assets were ¥890.3 billion (up ¥0.8 billion from the previous year-end), total assets stood at ¥1,468.3 billion (down ¥21.2 billion from the previous year-end), and the equity ratio was 57.8% (57.4% for the previous year-end).

Net assets increased slightly as a result of the recorded net income offsetting the payment of dividends and decrease in valuation and translation adjustments.

Total assets were slightly lower than the previous year-end mainly due to the decrease in net unrealized gain on investment securities due to deterioration of the financial situation, and the decrease in property, plant and equipment that accompanied the transfer of assets of the Shizuoka Plant from Daiichi Sankyo Propharma Co., Ltd. to CMIC Co., Ltd.

## **(3) Qualitative Information about Forecasts of Consolidated Results for Fiscal 2010**

We have not revised the forecasts of the consolidated financial results for the fiscal year ending March 31, 2011 that were announced on May 12, 2010.

## **2. Other Information**

### **(1) Summary of Changes in Significant Subsidiaries**

Acquired by the Company on April 1, 2010, Asubio Pharma Co., Ltd. has been excluded from the consolidated subsidiaries from the first quarter under review.

### **(2) Summary of Simplified Accounting Methods as well as Specific Accounting Methods (Simplified accounting methods)**

#### **a. Method for valuating inventories**

Total inventories as of the end of the quarter are calculated using a rational method based on total physical inventories as of the end of the previous fiscal year omitting physical inventories.

b. Method for calculating depreciation of non-current assets

Depreciation expenses for assets that are depreciated using the declining-balance method are calculated by proportionally dividing the annual depreciation expenses.

c. Method for calculating income taxes, deferred tax assets and deferred tax liabilities

Concerning judgments on the possibility of collection of deferred tax assets, when it is recognized that there are no remarkable changes either to the management environment or similar since the end of the previous fiscal year or to circumstances such as temporary differences or other, the method uses forecasts of future earnings results or tax planning based on the previous fiscal year.

However, if it is recognized that there are remarkable changes either to the management environment or similar since the end of the previous fiscal year or to circumstances such as temporary differences or other, then the method uses forecasts of future earnings results or tax planning based on the previous fiscal year but adjusted to reflect this remarkable change.

**(Specific accounting methods for preparing the quarterly consolidated financial statements)**

Taxes are computed first by reasonably estimating the effective tax rate after applying tax effect accounting against income before income taxes and minority interests for the fiscal year including the first quarter under review, and next by multiplying the quarterly net income before income taxes and minority interests by such estimated effective tax rate.

Note that income taxes—deferred is included in income taxes.

**(3) Summary of Changes in Accounting Policies and Procedures, and Methods of Presentation**

Effective the period under review, the Company adopted the “Accounting Standard for Asset Retirement Obligations” (ASBJ Statement No. 18) and the “Guidance on Accounting Standard for Asset Retirement Obligations” (ASBJ Guidance No. 21), both issued by the Accounting Standards Board of Japan (ASBJ) on March 31, 2008.

The effect of this change on operating income, ordinary income and income before income taxes and minority interests was immaterial.

**(4) Summary of Material Events related to Assumption of Going-Concern**

Not applicable.

### 3. Quarterly Consolidated Financial Statements

#### (1) Consolidated Balance Sheets

(Millions of yen)

	As of June 30, 2010	As of March 31, 2010 (Summary)
<b>ASSETS</b>		
Current assets		
Cash and time deposits	124,201	100,996
Trade notes and accounts receivable	216,306	211,889
Marketable securities	225,819	236,541
Merchandise and finished goods	95,072	91,708
Work in process	16,957	16,783
Raw materials and supplies	33,582	34,733
Deferred tax assets	82,689	86,970
Other current assets	40,734	41,802
Allowance for doubtful accounts	(1,670)	(1,668)
Total current assets	833,694	819,757
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	121,332	126,589
Machinery, equipment and vehicles, net	44,105	44,538
Land	40,213	42,618
Construction in progress	23,190	22,294
Other, net	12,934	13,504
Net property, plant and equipment	241,774	249,546
Intangible assets		
Goodwill, net	71,040	73,769
Other intangible assets, net	99,866	107,117
Total intangible assets	170,907	180,887
Investments and other assets		
Investment securities	126,742	137,042
Prepaid pension costs	2,659	3,889
Deferred tax assets	76,434	81,758
Other	16,372	16,931
Allowance for doubtful accounts	(307)	(304)
Total investments and other assets	221,901	239,318
Total non-current assets	634,583	669,752
Total assets	1,468,277	1,489,510



(Millions of yen)

	As of June 30, 2010	As of March 31, 2010 (Summary)
<b>LIABILITIES</b>		
Current liabilities		
Trade notes and accounts payable	57,896	66,539
Convertible bond-type bonds with subscription rights to shares to be redeemed within one year	50,634	–
Short-term bank loans	33,793	19,988
Income taxes payable	9,427	10,643
Allowance for sales returns	645	583
Allowance for sales rebates	1,240	1,406
Allowance for contingent losses	1,600	1,600
Other current liabilities	145,646	168,050
Total current liabilities	300,883	268,812
Long-term liabilities		
Bonds payable	100,000	100,000
Convertible bond-type bonds with subscription rights to shares	–	49,534
Long-term debt	118,548	121,389
Deferred tax liabilities	28,281	29,237
Accrued employees' severance and retirement benefits	11,467	12,320
Accrued directors' severance and retirement benefits	129	132
Asset retirement obligations	150	–
Other long-term liabilities	18,522	18,574
Total long-term liabilities	277,098	331,189
Total liabilities	577,982	600,001
<b>NET ASSETS</b>		
Shareholders' equity		
Common stock	50,000	50,000
Capital surplus	105,194	105,194
Retained earnings	758,346	746,392
Treasury stock, at cost	(14,560)	(14,566)
Total shareholders' equity	898,980	887,020
Valuation and translation adjustments		
Net unrealized gain on investment securities	22,707	27,461
Deferred gains or losses on hedges	1,167	1,002
Foreign currency translation adjustments	(74,519)	(59,778)
Total valuation and translation adjustments	(50,643)	(31,314)
Subscription rights to shares	3,465	3,295
Minority interests	38,492	30,506
Total net assets	890,295	889,508
Total liabilities and net assets	1,468,277	1,489,510

## (2) Consolidated Statements of Income

(Millions of yen)

	First three months of fiscal 2009 (From April 1, 2009 to June 30, 2009)	First three months of fiscal 2010 (From April 1, 2010 to June 30, 2010)
Net sales	227,123	256,427
Cost of sales	62,510	64,057
Gross profit	164,613	192,370
Selling, general and administrative expenses		
Advertising and promotional expenses	25,552	22,861
Salaries and bonuses	27,947	27,926
Severance and retirement costs	2,846	2,588
Research and development expenses	45,113	43,596
Other	36,386	34,335
Total selling, general and administrative expenses	137,846	131,308
Operating income	26,766	61,061
Non-operating income		
Interest income	1,515	686
Dividend income	1,293	1,448
Foreign currency translation adjustments	–	844
Gain on valuation of derivatives	–	7,654
Other income	1,063	1,184
Total non-operating income	3,872	11,818
Non-operating expenses		
Interest expense	1,556	1,619
Loss on valuation of derivatives	12,777	–
Foreign exchange losses	7,862	–
Equity in net losses of affiliated companies	108	52
Other expenses	1,165	1,115
Total non-operating expenses	23,469	2,787
Ordinary income	7,168	70,093
Extraordinary income		
Gain on sales of non-current assets	302	661
Gain on sales of subsidiaries and affiliates' stocks	–	33
Gain on change in equity	–	32
Gain on sale of investment securities	1,844	3
Other income	–	96
Total extraordinary income	2,146	827
Extraordinary losses		
Loss on disposal of non-current assets	195	250
Loss on valuation of investment securities	–	3,153
Loss on impairment of long-lived assets	–	656
Environmental expenses	482	490
Restructuring loss	–	139
Loss on adjustment for changes of accounting standard for asset retirement obligations	–	139
Total extraordinary losses	677	4,830

(Millions of yen)

	First three months of fiscal 2009 (From April 1, 2009 to June 30, 2009)	First three months of fiscal 2010 (From April 1, 2010 to June 30, 2010)
Income before income taxes and minority interests	8,638	66,089
Income taxes	23,984	26,551
Income before minority interests	–	39,538
Minority interests in net income (loss) of consolidated subsidiaries	(8,906)	6,464
Net income (loss)	(6,439)	33,073

### (3) Consolidated Statements of Cash Flows

(Millions of yen)

	First three months of fiscal 2009 (From April 1, 2009 to June 30, 2009)	First three months of fiscal 2010 (From April 1, 2010 to June 30, 2010)
Cash flows from operating activities		
Income before income taxes and minority interests	8,638	66,089
Depreciation	10,550	10,629
Loss on impairment of long-lived assets	–	656
Amortization of goodwill	2,192	2,266
(Gain) loss on valuation of derivatives	12,777	(7,654)
Increase (decrease) in allowance for doubtful accounts	44	(52)
Increase (decrease) in accrued severance and retirement benefits	264	397
(Increase) decrease in prepaid pension costs	885	577
Interest and dividend income	(2,808)	(2,134)
Interest expense	1,556	1,619
(Gain) loss on sales of investment securities	(1,844)	(3)
(Gain) loss on valuation of investment securities	–	3,215
(Gain) loss on sales of subsidiaries and affiliates' stocks	–	(33)
(Gain) loss on sales and disposal of property, plant and equipment	(107)	(410)
Equity in net (income) losses of affiliated companies	108	52
(Increase) decrease in trade notes and accounts receivable	(8,519)	(8,482)
(Increase) decrease in inventories	(5,890)	(4,100)
Increase (decrease) in trade notes and accounts payable	(822)	(7,877)
Increase (decrease) in accounts payable and accrued expenses	(1,837)	(6,035)
Other, net	3,746	(8,855)
Subtotal	18,935	39,862
Interest and dividends received	3,158	2,151
Interest paid	(1,778)	(1,301)
Income taxes paid	(2,636)	(9,916)
Net cash provided by operating activities	17,679	30,796

(Millions of yen)

	First three months of fiscal 2009 (From April 1, 2009 to June 30, 2009)	First three months of fiscal 2010 (From April 1, 2010 to June 30, 2010)
Cash flows from investing activities		
Purchases of time deposits	(7,949)	(36,132)
Proceeds from maturities in time deposits	4,204	11,014
Purchases of marketable securities	(6,724)	(22,865)
Proceeds from sales of marketable securities	33,964	29,180
Acquisitions of property, plant and equipment	(5,422)	(6,866)
Proceeds from sales of property, plant and equipment	453	3,442
Acquisitions of intangible assets	(536)	(499)
Acquisitions of investment securities	(1,901)	(627)
Proceeds from sales of investment securities	5,014	7
Acquisition of investments in subsidiaries	–	(1)
Proceeds from sales of investments in consolidated subsidiaries resulting in changes in scope of consolidation	–	5,641
Payments for loans receivable	(162)	(1)
Proceeds from collection of loans receivable	151	0
Other, net	(163)	(711)
Net cash provided by (used in) in investing activities	20,929	(18,418)
Cash flows from financing activities		
Net increase (decrease) in short-term bank loans	(97,406)	11,864
Proceeds from long-term debt	318	–
Repayments of long-term debt	(151)	(2,051)
Proceeds from issuance of bonds	99,688	–
Purchases of treasury stock	(8)	(6)
Proceeds from sale of treasury stock	2	0
Dividends paid	(28,168)	(21,129)
Other, net	(50)	10
Net cash used in financing activities	(25,776)	(11,312)
Effect of exchange rate changes on cash and cash equivalents	173	(7,720)
Net increase (decrease) in cash and cash equivalents	13,006	(6,655)
Cash and cash equivalents, beginning of period	177,769	259,215
Cash and cash equivalents, end of period	190,776	252,559

#### (4) Note related to Assumption of Going-Concern

Not applicable.

#### (5) Segment Information

##### [Information by Operating Segment]

First three months of fiscal 2009 (from April 1, 2009 to June 30, 2009)

Information by operating segment has been omitted because the “Pharmaceuticals” segment accounts for over 90% of the total net sales and operating income.

##### [Information by Geographic Segment]

First three months of fiscal 2009 (from April 1, 2009 to June 30, 2009)

(Millions of yen)

	Japan	North America	Europe	India	Other	Total	Eliminations & corporate	Consolidated
Net sales								
(1) Outside customers	128,491	54,226	22,452	11,479	10,472	227,123	–	227,123
(2) Inter-segment sales and transfers	14,574	9,652	9,159	4,806	248	38,441	(38,441)	–
Total	143,066	63,879	31,611	16,286	10,721	265,565	(38,441)	227,123
Operating income (loss)	15,556	13,943	1,211	(3,185)	898	28,425	(1,658)	26,766

Notes:

1. Method of classifying geographic segments

Geographic segments are classified on the basis of geographic proximity.

2. Countries and regions included in each segment other than Japan

North America: the United States, Canada

Europe: Germany, the United Kingdom, France, Spain, Italy, Romania and others

India: India

Other: China, Taiwan, Brazil and others

3. Change in method of classifying geographic segments

Previously, countries and regions were classified as Japan, North America, Europe and Other, constituting four segments. However, as “India” region has increased its materiality due to an expansion of the business size, “India” is, in order to represent its business activities more properly, now separately presented effective from the period under review.

Compared with the figures in the previous method, in Other regions, net sales decreased by ¥16,252 million (of which, the decrease in net sales to outside customers was ¥11,479 million) and operating income increased by ¥3,219 million. There were no effects on Japan, North America and Europe.

##### [Overseas Sales]

First three months of fiscal 2009 (from April 1, 2009 to June 30, 2009)

(Millions of yen)

	North America	Europe	Other	Total
I Overseas net sales	58,914	27,208	23,699	109,822
II Consolidated net sales				227,123
III Percentage of overseas net sales to consolidated net sales (%)	26.0	12.0	10.4	48.4

Notes:

1. Method of classifying countries and regions

Countries and regions are classified on the basis of geographic proximity.

2. Countries and regions included in each area

North America: the United States and Canada

Europe: Germany, the United Kingdom, France, Spain, Italy, Romania and others

Other: Asia, the Middle East, Latin America and others

3. Overseas net sales are sales of the Company and its consolidated subsidiaries which were transacted in countries or regions outside of Japan.

## [Segment Information]

### 1. Overview of reportable segments

The reportable segments of the Group are constituent units of the Company whose separate financial information can be obtained. The Board of Directors periodically examines these segments for the purpose of deciding the allocation of management resources and evaluating operating performance.

The Group's business operations are mainly comprised of the research & development, manufacture and sales of pharmaceutical drugs and OTC products. The two reportable segments of the Group are as follows: Daiichi Sankyo Group and Ranbaxy Group.

The Daiichi Sankyo Group, whose major members are the Company, Daiichi Sankyo, Inc., and Daiichi Sankyo Europe GmbH, operates pharmaceutical drugs and OTC products.

The Ranbaxy Group, centering on Ranbaxy Laboratories Ltd. operate s pharmaceutical drugs and OTC products.

### 2. Information concerning the net sales, and income/loss of each reportable segment

First three months of fiscal 2010 (from April 1, 2010 to June 30, 2010)

	(Millions of yen)		
	Daiichi Sankyo Group	Ranbaxy Group	Total
Net sales			
Outside customers	201,596	54,831	256,427
Inter-segment sales and transfers	18	66	85
Total	201,615	54,897	256,513
Segment income	39,955	27,622	67,578

### 3. Differences between the total amount of income/loss amounts of reportable segments and the amount stated in consolidated statements of income, and major breakdown of such differences (Reconciliation)

	(Millions of yen)	
Income or loss item	Amount	
Reportable segment total	67,578	
Amortization of purchase-price-allocation asset	(901)	
Amortization of goodwill	(604)	
Other adjustments	17	
Income before income taxes and minority interests stated in consolidated statements of income	66,089	

### (Additional information)

Effective the period under review, the Company adopted the "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (ASBJ Statement No. 17) issued by the ASBJ on March 31, 2009 and the "Guidance on Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (ASBJ Guidance No. 20) issued by the ASBJ on March 21, 2008.

## (6) Notes on Substantial Changes in the Amount of Shareholders' Equity

Not applicable.